- Home
- VTGN vs IMMX Comparison
VTGN vs IMMX Comparison
Compare VTGN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- IMMX
- Stock Information
- Founded
- VTGN 1998
- IMMX 2014
- Country
- VTGN United States
- IMMX United States
- Employees
- VTGN N/A
- IMMX N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- VTGN Health Care
- IMMX Health Care
- Exchange
- VTGN Nasdaq
- IMMX Nasdaq
- Market Cap
- VTGN 59.8M
- IMMX 61.1M
- IPO Year
- VTGN N/A
- IMMX 2021
- Fundamental
- Price
- VTGN $2.09
- IMMX $2.55
- Analyst Decision
- VTGN
- IMMX Strong Buy
- Analyst Count
- VTGN 0
- IMMX 1
- Target Price
- VTGN N/A
- IMMX $7.00
- AVG Volume (30 Days)
- VTGN 193.9K
- IMMX 145.9K
- Earning Date
- VTGN 08-12-2025
- IMMX 08-11-2025
- Dividend Yield
- VTGN N/A
- IMMX N/A
- EPS Growth
- VTGN N/A
- IMMX N/A
- EPS
- VTGN N/A
- IMMX N/A
- Revenue
- VTGN $486,000.00
- IMMX N/A
- Revenue This Year
- VTGN N/A
- IMMX N/A
- Revenue Next Year
- VTGN $943.32
- IMMX N/A
- P/E Ratio
- VTGN N/A
- IMMX N/A
- Revenue Growth
- VTGN N/A
- IMMX N/A
- 52 Week Low
- VTGN $1.90
- IMMX $1.26
- 52 Week High
- VTGN $4.21
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- VTGN 39.11
- IMMX 61.17
- Support Level
- VTGN $1.97
- IMMX $2.16
- Resistance Level
- VTGN $2.07
- IMMX $2.31
- Average True Range (ATR)
- VTGN 0.14
- IMMX 0.18
- MACD
- VTGN -0.01
- IMMX 0.00
- Stochastic Oscillator
- VTGN 12.00
- IMMX 92.59
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.